Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chinese real-world registry study of daratumumab in multiple myeloma
ChiCTR2200055491Phase 4Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of daratumumab in multiple myeloma (MM), sponsored by Peking University People's Hospital. Primary endpoint: Tumor remission rate. Started Jan 2022; status: recruiting.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2200055491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200055491.